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ABSTRACT
Ovarian cancer (OvCa) is a challenging disease to treat due to poor screening techniques and late diagnosis. There is an urgent need for
additional therapy options, as patients recur in 70% of cases. The limited availability of clinical treatment options could be a result of poor
predictions in early stage drug screens on standard tissue culture polystyrene (TCPS). TCPS does not capture the mechanical and
biochemical cues that cells experience in vivo, which can impact how cells will respond to a drug. Therefore, an in vitro model that captures
some of the microenvironment features that the cells experience in vivo could provide better insights into drug responses. In this study, we
formed 3D multicellular tumor spheroids (MCTS) in microwells and encapsulated them in 3D omentum-inspired hydrogels. SKOV-3
MCTS were resistant to Paclitaxel in our 3D hydrogels compared to a monolayer on TCPS. Toward clinical application, we tested cells from
patients [ovarian carcinoma ascites spheroids (OCAS)] who had been treated with Paclitaxel, and drug responses predicted by using the 3D
omentum-inspired hydrogels demonstrated the lack of the Paclitaxel response of these samples. Additionally, we observed the presence of
collagen production around the encapsulated SKOV-3 MCTS, but not significantly on TCPS. Our results demonstrated that our 3D
omentum-inspired hydrogel is an improved in vitro drug testing platform to study the OvCa drug response for patient-derived cells and
helped us identify collagen 3 as a potential driver of Paclitaxel resistance in 3D.
VC 2019 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://
creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/1.5091713
INTRODUCTION
Ovarian cancer (OvCa) is the fifth deadliest cancer for women,
and the deadliest gynecological disease for women overall, resulting in
an estimated 14 070 deaths in the United States in 2018.1 The high
mortality rate of OvCa is due to late detection, inadequate screening
techniques, and a lack of effective second line therapies.2 OvCa is typi-
cally detected very late, partially because the disease is asymptomatic
until Stage III,3 when the cancer cells are no longer confined to the
ovaries. At the time of staging laparectomy, metastases that have
spread through the peritoneum are present in 70% of patients.3 It has
been accepted in the field that tumor cells spread into the peritoneal
fluid, where they form ovarian carcinoma ascites spheroids (OCAS),
and can attach onto the abdominal peritoneum or omentum.4,5 While
aggregation has been accepted for model OCAS formation, recent
work demonstrated that detachment of clusters from the primary
tumor may be the more likely source of OCAS in the abdomen.6
Regardless of the OCAS formation method in vivo, prognosis for
OvCa patients has improved little in the last three decades since the
introduction of platinum-based treatments.7 Although first line ther-
apy results in complete remission in 40%–60% of patients, over
70% of those patients relapse within two years, and there are no effec-
tive second line treatments.8,9 Additionally, to our knowledge, only
four targeted drugs have been approved by the Food and Drug
Administration (FDA) in the last ten years for OvCa treatment. There
is a clear need for innovation in drug discovery to develop additional
OvCa treatments to improve patient outcomes.
A possible reason for the inadequate success in OvCa drug dis-
covery is that current preclinical in vitro screening methods are not
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good predictors of clinical success of drug candidates. Many hypothe-
size that this is largely because in vitro screening uses cell lines grown
on tissue culture polystyrene (TCPS).10,11 The TCPS surface has no
resemblance to the in vivo microenvironment chemically, physically,
or topologically.12 Cancer cells grown in this environment have differ-
ent morphologies, phenotypes, cellular signaling, and drug responses
from cells found in vivo.13 Three-dimensional (3D) culture models are
increasingly used in basic science applications because they offer envi-
ronments that better resemble in vivo conditions,14,15 and they can be
tuned to model different tissues.16,17 Most 3Dmodels consist of hydro-
gels or similar biomaterials that have a 3D structure inside which can-
cer cells can be grown.18–21 These materials can be functionalized with
peptides to mimic cell-extracellular matrix (ECM) interactions, ECM
degradability, and other in vivo properties.22,23
There are several types of 3D models in which cancer multicellu-
lar tumor spheroids (MCTS, which resembles OCAS) can be grown
in vitro.24 Incorporating MCTS grown from established cell lines may
also better model the in vivo microenvironment for drug screening
than TCPS. However, the use of established cell lines does not capture
disease heterogeneity across patients25 and the lack of clinical relevance
of cell lines is becoming increasingly apparent26 despite their wide-
spread use for in vitro studies.27 For this reason, in vitro models of
OvCa tissue coupled with patient-derived OCAS compared with tradi-
tional screening methods could improve OvCa drug discovery.28 Thus,
they would promise fewer false leads and so better drug discovery.
While genetic mechanisms of OvCa have been studied,29 these findings
alone have not been sufficient for explaining the drug response.30 The
use of primary cells isolated from patients would improve testing of
drugs in a more personalized way.31 Ascites fluid in the peritoneal cav-
ity of OvCa patients is rich in single malignant cells and OCAS,32,33
and this fluid is often drained to relieve the pain it causes. In this study,
we evaluated the response of SKOV-3 OvCa MCTS and patient-
derived OCAS to several drugs across different mechanisms of action
in synthetic, tailorable hydrogels. Through this study, we revealed a
nonintuitive response of patient cells to these drugs, and we nominate
collagen 3 as a particularly interesting ECM protein potentially driving
resistance to Paclitaxel in 3D. These hydrogels are easy to create and
support the viability and survival of patient-derived OCAS, and we
propose this as a useful system to preclinically screen drug candidates.
RESULTS
OvCa MCTS were viable and proliferative in 3D
poly(ethylene glycol)-maleimide (PEG-MAL) hydrogels
OvCa metastasizes to several sites within the peritoneal cavity.4
Here, we chose to focus on the omentum due to the availability of pub-
lished data on this tissue of OvCa metastasis, which we used to design
our 3D hydrogel model. Since OvCa metastasizes to the omentum as
aggregated cells,33 we hypothesized that a 3D hydrogel with integrin-
binding peptides found in the omentum would support the viability
and proliferation of OvCa MCTS (Fig. 1). We previously used three
methods for creating MCTS from established cell lines,24 and here, we
chose to use the microwell formation method [Fig. 1(a)]. At the time of
the design of this study, aggregation was accepted to be more akin to
how OvCa form OCAS (aggregated single cells rather than clonal
growth from a single cell) in vivo during metastasis,33 but aggregates
may actually detach from the primary tumor as clusters.6 Our previous
work demonstrated that the microwell formation method is fast
(MCTS form within one day) and resulted in the most uniform size
distribution of MCTS.24 For this study, we selected the widely used
SKOV-3 OvCa cell line to form MCTS. We then chose to encapsulate
these MCTS in 3D poly (ethylene glycol)-maleimide (PEG-MAL)
hydrogels to capture a physiologically relevant stiffness (approximately
FIG. 1. Three biomaterial platforms that were used to evaluate the SKOV-3 drug
response. (a) Schematic of the MCTS formation method and the experimental setup
for drug screening MCTS encapsulated in 3D PEG-MAL hydrogels. (b) Schematic of
the components of a 3D PEG-MAL hydrogel with encapsulated SKOV-3 MCTS within
a 3D hydrogel. (c) Omentum-inspired integrin-binding peptide cocktail based on healthy
omentum proteomic data. (d) Schematic of cells grown on plastic or encapsulated in a
3D hydrogel model. (e) LIVE (green)/DEAD (red) imaging of cells in each platform one
day postencapsulation. (f) Ki67 (pink)/DAPI (blue) staining of cells one day postencap-
sulation to evaluate cell proliferation. Scale bar ¼ 100 lm. Images are representative
from N  2 independent experiments.
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2kPa)22,34 with a high water content, as well as tailored integrin-
binding and matrix degradability. Since PEG hydrogels are not inher-
ently degradable by cells, it was necessary to incorporate a cell-
degradable cross-linking sequence during hydrogel synthesis to facili-
tate cell survival and spreading within the matrix. For this study, we
selected a Pan-matrix metalloproteinase (Pan-MMP) degradable pep-
tide cross-linker that can be degraded by many MMPs at the glycine-
isoleucine bond.35 To optimize MCTS survival, we varied the amount
of Pan-MMP degradable cross-linking within the hydrogel that con-
tained RGD peptide integrin-binding [Fig. S1(a)]. The total cross-
linking was kept at a 1:1 molar ratio of maleimide-functional end
groups to thiol-functional end groups by completing the cross-linking
solution with linear PEG-dithiol (PDT), while the amount of Pan-
MMP degradable cross-linking was varied. From our data, we con-
cluded that 12 mol. % Pan-MMP degradable cross-linking supported
MCTS survival and we used this condition for all subsequent experi-
ments unless otherwise noted.
We tested encapsulating MCTS from one (5500 MCTS/ml
approximate), two (11 000 MCTS/ml), or three (16 500 MCTS/ml)
wells of the 12-well plate containing microwells into six PEG-MAL
hydrogels with RGD peptide integrin-binding and 25 mol. % Pan-
MMP degradable cross-linking with the remainder of the cross-
linking with linear PDT. We found that the ratio of one well from the
12-well plate to six PEG-MAL hydrogels (approximately 500 MCTS
per hydrogel) was ideal for a CellTiter-Glo output signal where we
would be able to detect changes in the MCTS response with varying
drug concentrations. Additionally, we found that the relative change
in the output signal from day one to day three was approximately the
same for each ratio of wells from the microwells plate to six PEG-
MAL hydrogels [Fig. S1(b)]. We used approximately 500 MCTS per
PEG-MAL hydrogel for the remainder of this study. This allowed us
to test as many conditions as possible using one 12-well microwells
plate and did not reduce the quality of the final assay measurement.
We measured the drug response of SKOV-3 MCTS in a 3D PEG-
MAL hydrogel with RGD integrin-binding, but we hypothesized that
adding tissue specificity could provide a better environment for MCTS
survival, and therefore, the drug responses would be more representa-
tive of what would occur in vivo. We therefore increased the complex-
ity of the 3D hydrogel model by adding additional integrin-binding
peptides specific to the omentum, which is the site of many OvCa
metastases.4 We aimed to create a 3D hydrogel with some tissue specific-
ity without being overly complex, which would potentially limit future
applications in drug screening or in a clinical setting. To find the most
abundant integrin-binding proteins in the omentum, we mined pub-
lished mass spectrometry data of healthy omentum tissue.36 The full
integrin-binding peptide cocktail is described in Fig. 1(c). GFOGER,
which is the binding sequence in collagen 1 and other fibrillar colla-
gens,37 comprises a majority of the hydrogel, but this cocktail contains
RGD, as well as PHSRN-RGD and DGEA representative of other pro-
teins described in Fig. 1(c). For simplicity, we kept the Pan-MMP
degradable cross-linker used with the RGD only integrin-binding hydro-
gel to allow for MCTS to degrade the surrounding hydrogel.
Since this omentum-inspired hydrogel is new to the field, we first
ensured that cells were viable and proliferative before drug screening,
alongside two other platforms as internal controls [Fig. 1(d)]. As
expected, SKOV-3 cells cultured on TCPS showed high viability and
proliferation indicated by LIVE/DEAD and Ki67 staining, respectively
[Figs. 1(e) and 1(f)]. Both our PEG-MAL hydrogel models supported
cell survival with very few dead cells inside the MCTS. Additionally,
we observed proliferating cells throughout the MCTS by Ki67 staining
[Fig. 1(f)]. These results allowed for subsequent drug screening experi-
ments in these platforms.
SKOV-3 OvCa MCTS were resistant to Paclitaxel
and sensitized to other drugs in the 3D PEG-MAL
hydrogels relative to TCPS
As a control, we first established drug responses of the SKOV-3
cells to five drugs, spanning different mechanisms of action, on TCPS
(Figs. 2 and S2-3). We quantified the IC50, EC50, and GR50 (Ref. 38)
(Fig. S2) for each cell line and drug combination using the online GR
calculator.39 We calculated and reported these three parameters
because they each provided different information about the potency of
the drug on the cell line.38 In all cases, the GR50 was lower than the
IC50 and EC50 metrics (Fig. S2), because the GR50 is quantifying the
reduction in the growth rate and not overall inhibition of the cell num-
ber. We found that SKOV-3 MCTS did not respond to Paclitaxel in
the 3D hydrogels [EC50, Figs. 2(b) and S4-5] but had an average EC50
of 12.1lM on TCPS. We chose to report and compare the EC50 for
each condition since it is the concentration that corresponds to achieve
half of the maximal response and does not require at least 50% cell
death as the IC50 does.
38 This means that the drug responses across
multiple conditions could still be compared if the cells did not grow
exponentially over the course of the experiment or if greater than 50%
cell death relative to the control was not achieved, which is required for
calculating the GR50 and IC50, respectively. We found that it was not
possible to calculate the GR50 in many of the 3D cases that we tested.
Since Paclitaxel is a first-line therapy for OvCa patients, we were sur-
prised to see a lack of response of SKOV-3 MCTS in our hydrogel
models to this chemotherapy. However, OvCa Paclitaxel resistance has
been previously reported in another 3D model by Loessner et al.40 This
observation is important because the drug response curve for SKOV-3
with Paclitaxel on TCPS is typical [Fig. S3(b)], making it appear effica-
cious, but the curve looks strikingly dissimilar in a 3D culture model.
Surprisingly, we found that the MCTS in the hydrogels were
more sensitive to all the other drugs that we tested, relative to TCPS
(EC50, Figs. 2 and S4-5). SKOV-3 MCTS were more sensitive (lower
EC50) to Carboplatin and Doxorubicin [Figs. 2(a) and 2(c)] in the
omentum hydrogel than in the RGD hydrogel. On the other hand,
MCTS were more sensitive to LY2606368 and Mafosfamide [Figs. 2(d)
and 2(e)] in the omentum hydrogel than on TCPS although MCTS
were less sensitive to Mafosfamide in the omentum hydrogel com-
pared to the 3D RGD hydrogel; note that these compounds have not
yet become clinically approved for OvCa treatment. An expanded
future study with these models and other drugs, both clinically
approved and in development, could possibly be used to make correla-
tions between preclinical studies and clinical efficacy in patients.
Patient-derived OCAS drug sensitivity reflected the
real clinical response in omentum-mimicking
hydrogels
Our goal was to evaluate how OCAS from patient samples
responded to the drugs in our study in the 3D omentum-inspired
hydrogel relative to TCPS. We collaborated with the team at UMass
APL Bioengineering ARTICLE scitation.org/journal/apb
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Medical School to obtain ascites fluid from OvCa patients who had
undergone paracentesis. Ascites is a fluid rich in single cells, OCAS, and
soluble factors, which can be processed to collect the different compo-
nents.32 The cells in ascites are a particularly valuable material for drug
screening since they are a fairly accessible source of primary cells to study
OvCa. To isolate cells and OCAS for drug screening purposes, we proc-
essed the ascites using centrifugation, removal of red blood cells, and
washing steps, which has been described in detail previously.24 We then
encapsulated OCAS into 3D omentum hydrogels and compared their 3D
drug responses with those of TCPS (Fig. 3). The basic pathology reports
for the patient samples are listed in Fig. 3(a). Prior to drug screening, sam-
ples were assessed for viability via LIVE/DEAD staining [Fig. 3(b)], which
showed high viability across all samples in the 3D PEG-MAL omentum
hydrogels. We observed that samples from patient 1 were resistant to
Mafosfamide, but sensitive to LY2606368 in the 3D hydrogel relative to
TCPS [Figs. 3(c) and S6]. LY2606368 is an inhibitor that is currently in
Phase II clinical trials for OvCa.41,42 However, upon receiving the next
sample (patient 12 was the same as patient 1 with six weeks between sam-
ple collection), resistance in 3D vs on TCPS increased for these two drugs.
Patient 2 received both Carboplatin and Paclitaxel [Fig. 3(a)]. Our 3D
omentum hydrogel model demonstrated sensitivity to Carboplatin,
Doxorubicin, LY2606368, and Mafosfamide relative to TCPS and only
slight resistance to Paclitaxel. If patient 2 did not respond to these drugs
in the clinic (Carboplatin and Paclitaxel) and the response was not depen-
dent on geometry, we would expect a lack of responses both on TCPS
and in 3D. Because of IRB restrictions, we did not obtain final patient out-
come information, but we did see responses to these drugs in our study
(Fig. S6). Interestingly, Doxorubicin, LY2606368, and Mafosfamide all
appeared to be more effective in 3D vs 2D for the patient 2 sample. Since
we observed a decreased response to LY2606368 and Mafosfamide in 3D
relative to TCPS with the samples from patient 1, it may indicate that our
hydrogel model could be a way to predict potential drug responses of
patients as the disease progresses. Screening to obtain this type of infor-
mation could be a way to help guide future clinical treatment decisions.
However, many more samples would be required to establish generalized
observations of eventual prognostic value.
SKOV-3 MCTS expressed ECM proteins in 3D hydrogels
To explore possible reasons for the differences in drug responses
that we observed, we quantified the presence of a subset of ECM pro-
teins via immunofluorescence staining (Fig. 4). Fibronectin has been
FIG. 2. Quantified SKOV-3 drug response
reported as EC50 on TCPS or as MCTS
encapsulated in RGD or omentum-
inspired peptide-binding 3D PEG-MAL
hydrogels. (a) Carboplatin. (b) Paclitaxel.
(c) Doxorubicin. (d) LY2606368. (e)
Mafosfamide. Data are reported as the
mean 6 SEM. The EC50 values were cal-
culated using the online GR calculator and
from N  2 independent experiments with
N ¼ 3 technical replicates on TCPS and
N  2 technical replicates in hydrogels.
Statistical significance where p 0.01 is
denoted with **.
APL Bioengineering ARTICLE scitation.org/journal/apb
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shown to be produced by mesothelial cells to promote OvCa metasta-
sis,43 and we observed fibronectin production on TCPS and in 3D
hydrogels by the OvCa cells themselves [Fig. 4(a)]. By visual inspec-
tion, in both 3D hydrogel models, it appeared that the fibronectin was
localized to within the MCTS rather than around the MCTS surface.
Collagen 1 is a major component of the omentum microenviron-
ment,36 and the work by Januchowski et al. discovered fibrillar colla-
gen genes and, in particular, collagen 3A1 was upregulated in
Topotecan- and Paclitaxel-resistant OvCa cells on TCPS.44 Therefore,
we looked for both extracellular collagen 1 and collagen 3 (detected by
collagen 1 and collagen 3A1 antibodies, respectively) in the environ-
ments tested here. We found that in the 3D hydrogels, but not on
TCPS, SKOV-3 cells produced collagen 1 [Fig. 4(b)]. This suggests
that perhaps the SKOV-3 MCTS were working to produce their own
fibrillar collagen 1 for survival since GFOGER does not provide a
fibrillar structure for the cells to most effectively bind. Furthermore,
we observed some collagen 3A1 on TCPS on day 3, whereas it was
highly expressed in both 3D conditions around and within the MCTS
at both timepoints [Fig. 4(c)]. Since gene expression of this protein
was upregulated for Paclitaxel resistant cell lines on TCPS,44 perhaps
we are demonstrating that these MCTS produce collagen 3A1 to
become Paclitaxel resistant in 3D. These results suggest that SKOV-3
cells may produce their own ECM proteins to increase their survival to
prevent the response to Paclitaxel exposure in 3D. Future work could
examine a larger panel of ECM proteins to attempt at correlating the
presence on specific proteins and OvCa drug resistance in 3D
microenvironments.
DISCUSSION
There is clear room for improvement in OvCa treatment. The
availability of ascites from OvCa patients provides a valuable opportu-
nity for developing an improved OvCa drug testing pipeline that com-
bines patient cells and engineered environments. Others have
recognized the need for developing more clinically relevant OvCa drug
FIG. 3. OvCa samples derived from
patient ascites were encapsulated in 3D
omentum-inspired PEG-MAL hydrogels
for drug screening. (a) Pathology report of
patient samples. (b) LIVE (green)/DEAD
(red) imaging of OCAS in 3D omentum
PEGMAL hydrogels one day postencap-
sulation. Scale bars ¼ 100 lm. Images
are representative from the sample. (c)
Patient sample drug responses displayed
as the log2 fold change in EC50 in the
omentum hydrogel relative to EC50 on
TCPS. Red and blue indicate the higher
and lower EC50 values in the 3D omentum
hydrogel relative to the EC50 on TCPS,
respectively.
APL Bioengineering ARTICLE scitation.org/journal/apb
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screening platforms.40,45 Similar to our RGD hydrogel, Loessner et al.
evaluated the response of SKOV-3 MCTS to Paclitaxel in a 3D PEG-
based hydrogel with RGD binding sites and MMP-degradable sites.40
The MCTS generation approach was different from ours where their
platform allowed for the formation of the MCTS from single cells
within the PEG hydrogel over 12 days rather than by the aggregation
and encapsulation method that we used.40 Even with a different 3D
hydrogel and the MCTS formation method, they also observed resis-
tance to Paclitaxel in 3D.40 However, they did not test the response to
other drugs in their study, which limits what we can compare between
studies. Liu et al., with 3D collagen gels, observed resistance of OV-
NC and OV-206 OvCa cell lines seeded as single cells in 3D to
Paclitaxel, Carboplatin, and 5-fluorouracil relative to TCPS.46
Furthermore, the use of this collagen gel demonstrated that the ability
of OvCa to interact with the collagen matrix increased the invasive
capacity of the cells.46 From this observation and our collagen staining
results, it appears that collagen 1 is necessary for OvCa disease pro-
gression and/or drug resistance in 3D and OvCa cells will produce this
protein themselves if it is not provided within the biomaterial environ-
ment. To model the omentum for understanding OvCa metastasis, a
multicellular platform containing mesothelial cells, fibroblasts, and
ECM was developed.47 The application of this platform identified that
mesothelial cells from the omentum caused inhibition and fibroblasts
and ECM promoted attachment and invasion of OvCa cells.47 In the
context of OvCa drug screening and the omentum microenvironment,
we see our study as a valuable contribution to OvCa drug response
research because we compare OCAS derived from ascites with cell line
MCTS to aid in establishing links between preclinical drug screening
models and clinical responses.
We suggest that our synthetic hydrogel model holds potential as
a good tool for screening the patient OCAS drug response. By control-
ling the polymer concentration of the 3D hydrogels, we were able to
test the samples encapsulated in hydrogels with a stiffness of 2.3
6 1.9 kPa,22 which is physiologically relevant for omental tissue [2.9
6 1.5 kPa (Ref. 34)]. Furthermore, the 3D PEG-MAL hydrogels are
easy to make because all the peptides and polymer precursors can be
made in advance and simply require dissolution for sample encapsula-
tion. Thus, whenever patient samples are available, one can process
the sample and complete the encapsulation within a few hours.
Additionally, an ascites sample has limited OCAS material for screen-
ing, which makes our small volume hydrogel system useful for screen-
ing multiple compounds. If multiple treatment options are being
considered for a patient, then this could be a simple, but valuable tool
in guiding the selection of the next treatment steps. For example,
LY2606368 is currently in Phase II clinical trials41,42 and could be an
option for patients in the future. Testing this compound in 3D hydro-
gels demonstrated that it was more promising as a patient treatment
than screening only on TCPS by comparing the reported EC50 values
[Fig. 3(c)]. Furthermore, patient sample 12 was received about 6weeks
after patient sample 1, and we observed an increase in resistance to the
drugs that we tested. Our results imply that as disease progresses, the
patient’s ability to respond to treatment decreases for these particular
samples. To our knowledge, Mafosfamide has never been tested in
clinical trials for OvCa but has shown promise in vitro on TCPS.48,49
We could not find any additional information about further preclinical
studies of this drug. We can only speculate that there may have been
unpublished animal studies where Mafosfamide was not effective. We
were interested in testing Mafosfamide as an example of a potential
treatment for OvCa with our tissue-specific hydrogel system and
found cells in the 3D hydrogel more sensitive to this drug compared
to TCPS. The results from our 3D hydrogel approach suggest that this
drug could be beneficial for patients, and this prediction of efficacy
was likely not identified with earlier studies that relied solely on TCPS
[Figs. 3(c) and S6]. If the additional integrin-binding peptides of
the omentum hydrogel more faithfully capture the in vivo microenvi-
ronment, then this could potentially help explain how some
FIG. 4. Immunofluorescence staining of SKOV-3 cells demonstrated that they pro-
duce their own ECM proteins over the time frame of a drug screening assay. (a)
Fibronectin (green)/DAPI (blue). Fibronectin can be seen on plastic as well as
between cells in the MCTS. (b) Collagen 1 (green)/DAPI (blue). Collagen 1 produc-
tion was not observed on plastic but was visible around the spheroids. (c)
Collagen3A1 (pink)/DAPI (blue). Some collagen 3A1 may be present on plastic but
is clearly visible surrounding the spheroids in both hydrogels. Scale bars ¼ 100
lm. Images are representative from N  2 independent experiments.
APL Bioengineering ARTICLE scitation.org/journal/apb
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compounds have been able to successfully become clinical OvCa treat-
ments. However, it should be noted that the added complexity of addi-
tional integrin-binding peptides in the omentum hydrogel was not
necessary for observing the SKOV-3 resistant to Paclitaxel in 3D.
From our experiments, however, it is not clear if the 3D MCTS struc-
ture or if the 3D hydrogel environment is driving this lack of response
across the range of concentrations of Paclitaxel what we tested.
Overall, we suggest that our approach could and should be extrapo-
lated to more possible OvCa drugs either originally overlooked or cur-
rently under consideration/development.
In our previously published work, we compared differences in
gene expression of MCTS created using a variety of different methods
(i.e., clonal growth in polyNIPAAM vs aggregation in microwells).24
In this first generation approach, we created MCTS by clonal growth
from SKOV-3 cells and compared their response and the response of
OCAS from patients with a small panel of drugs in a nondegradable,
RGD integrin-binding, 3D synthetic PEG hydrogel.24 The results sug-
gested that further exploration of OvCa in a 3D model may be useful
for understanding the drug response in patient samples. Here, we used
microwells, an aggregation formation method, to create MCTS since
OCAS may form by aggregation in patients.33 By simply encapsulating
the cells and OCAS from ascites, we preserved the cell-cell contacts
and any associated ECM directly from the patient. Because we were
limited in sample sizes, we are unsure of how much ECM comes with
the OCAS, but we observed that the SKOV-3 cell line had the presence
of secreted fibronectin, collagen 3, and collagen 1 within one day of
encapsulation (Fig. 4). Since these ECM proteins were not seen on
TCPS for all these cases, we suspect that ECM production facilitated
survival in 3D by adding new integrin-binding sites in addition to
those we provided via peptides. Our results aid in identifying collagen
3 as an important contributor to OvCa drug resistance since it was
identified to be coexpressed with the ECM protein lumican in a
Topotecan-resistant OvCa cell line on 2D by another research group.50
Perhaps this suggests that future work could potentially explore how
these ECM proteins directly impact the OvCa response to drug.
It has been well-established that cells grow at different rates in
2D and 3D cultures.13,51 Since the ability of cells to respond to chemo-
therapy is proliferation-dependent, the response is expected to vary
depending on growth conditions. To account for differences in growth
rates that will impact the measurements for traditional drug screening
metrics, the GR50 was established.
39 One key condition that must be
met when applying this analysis is that the cells are growing exponen-
tially over the course of the assay.39,52 We have found that this key
condition is not always met, especially in biomaterial platforms, and
has discussed this in further detail.38 In this study, we were not able to
calculate the GR50 for all the conditions that we tested due to growth
limitations. Therefore, the EC50 is what we were able to report here for
all the conditions that we tested. Due to the differences in growth rates
of cells in 2D and 3D, our 3D model helps aid in understanding
growth of the MCTS in 3D in vitro before moving to in vivo studies.
We tested drugs used clinically to treat patients, a drug that is in clini-
cal trials, and Mafosfamide, which has shown promise in vitro on
TCPS,48,49 but to our knowledge, has never been studied in clinical tri-
als. As more people come to know about how the microenvironment
impacts the drug response, it may be possible to evaluate additional
quantitative phenotypes that would aid in comparing drug responses
across different geometries. Others have created models with other cell
types including mesothelial cells and fibroblasts,47,53,54 but here our
system was focused on the parameters of integrin-binding sites, stiff-
ness, and 3D geometry without the contribution of other cells present
within the omentum microenvironment. Since ascites is rich in cyto-
kines and growth factors,32 perhaps future studies with patient-derived
OCAS could incorporate ascites-derived cytokines as an additional
feature for more faithfully modeling the omentum microenvironment
for OvCa drug screening. By evaluating the presence of a subset of
ECM proteins in addition to the EC50 for each condition, we have
enabled an approach to couple the microenvironment composition
and drug response, which could be applied in other drug screening
studies with biomaterials. This could help establish large drug response
and ECM composition data sets, which could then possibly be used to
determine correlations between the ECM composition and the drug
response that may aid in making better clinical predictions for the suc-
cess of a drug candidate.
OvCa is a challenging disease to treat and the development of
second line therapies is critical since recurrence occurs in a majority of
patients. We propose that this can be achieved by using a 3D PEG-
MAL hydrogel with encapsulated MCTS to aid in making better
preclinical predictions for new therapeutic compounds. Our results
demonstrated that screening for therapies on TCPS and in 3D hydro-
gels did not yield the same drug responses. This observation may be
dependent on the ECM composition, and we concluded that TCPS
may not be sufficient for evaluation of the OvCa drug response. Most
patients have the presence of ascites, which is removed as part of treat-
ment and contains many OCAS. The integration of OCAS in an
omentum-inspired 3D hydrogel model to study the drug response
yielded results that are also different from those of TCPS. We discov-
ered that our 3D hydrogel model demonstrated drug response results
that we could not have captured on TCPS alone and recommend that
future OvCa drug screens employ our materials to aid in understand-
ing the OvCa response in vitro.
METHODS
Cell culture
All cells were maintained at 37 C and 5% CO2, and all cell cul-
ture supplies were purchased from Thermo Fisher Scientific
(Waltham, MA) unless otherwise noted. The SKOV-3 cell line was
purchased from the American Type Culture Collection (ATCC,
Manassas, VA). SKOV-3 cells were grown in Roswell Park Memorial
Institute (RPMI) medium supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin (pen/strep).
Primary ovarian cancer ascites culture
Ascites samples were received from patients undergoing para-
centesis at UMass Medical School (Worcester, MA), transported to
UMass Amherst the same day as the procedure and used for experi-
ments immediately upon receipt. Samples were deidentified and were
IRB exempt. Pathology reports are provided in Fig. 3(a). Single cells
and OCAS were recovered from patient samples and treated as
described previously.24 Samples containing both single cells and
OCAS were grown on 2D TCPS or encapsulated directly into 3D
PEG-MAL hydrogels. All experiments with primary OvCa samples
were conducted as one biological replicate with RPMI þ 10% FBS
þ 1% pen/strep.
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Microwell MCTS
Square pyramidal microwells (400lm sidewall dimension) were
fabricated as described previously.55 Briefly, master molds containing
square-pyramidal pits were generated by anisotropic etching of 100
crystalline silicon in potassium hydroxide (KOH). Microwells were
generated from poly(dimethylsiloxane) (PDMS) using a two-stage rep-
lica molding process of the master mold as described previously.55
Microwells were arranged in a square array with no space between
adjacent wells and placed in 12-well plates. For cell seeding, microwell
surfaces were UV sterilized for 30min, pretreated with 5% Pluronic F-
127 (Sigma-Aldrich, St. Louis, MO) for 5min at 3500 RPM (2465g,
Eppendorf 5810R v3.3 centrifuge with A-4-62 rotor, Eppendorf,
Hamburg, Germany) with an additional 30-min incubation on the
bench, and then washed twice with sterile water. Cells were seeded
1.00 105 cells/well (approximately 26 000 cells/cm2). After 24 h,
MCTS were collected by shaking the plate gently to dislodge most of
them and gently aspirating medium and MCTS. MCTS solution was
spun down at 400 RPM (Thermo Scientific Sorvall ST16R centrifuge)
for 5min. Medium was removed, MCTS were encapsulated in 3D
hydrogels, and RPMI þ 5% FBS þ 1% pen/strep was added to each
well after the hydrogels had polymerized.
3D PEG-MAL hydrogel platform
MCTS or OCAS were encapsulated into 3D PEG hydrogels as
described previously24 with minor modifications. The 3D RGD hydrogel
was prepared with a 20kDa 4-arm PEG-maleimide (PEG-MAL, Jenkem
Technology, Plano, TX) at 10wt. % solution [measured Young’s modu-
lus at this condition was 2.36 1.9 kPa (Ref. 22) and corresponds to the
initial average measured elastic modulus of omental tissue of 2.9 6 1.5
kPa (Ref. 34)]. The RGD hydrogels also included 2mM of cell adhesion
peptide GSPCRGDG (RGD, Genscript, Piscataway, NJ) and cross-linked
with a 90mM combination of the 1kDa linear PEG-dithiol (JenKem,
79.2mM) and cell-degradable cross-linker, Pan-matrix metalloproteinase
(Pan-MMP, GCRDGPQGIWGQDRCG, Genscript, 10.8mM)35 in ster-
ile 2mM triethanolamine (pH 7.4). The hydrogels were synthesized by
pipetting 1ll of PDT and Pan-MMP solution onto the well surface of a
48-well TCPS plate, followed by pipetting 9ll of the MCTS/OCAS-con-
taining PEG—MAL solution. The 3D omentum hydrogel was prepared
with 2mM of the omentum integrin-binding peptide cocktail. The
omentum cocktail is fully described in Fig. 1(c) and consists of
(GRGDSPCG, Genscript), GFOGER (CGP(GPP)5GFOGER(GPP)5,
Genscript), PSHRN-RGD (CGPHSRNGGGGGGRGDS, the samemeth-
ods as described previously22), DGEA (GCGDGEA, the same methods
as described previously22). The MCTS from microwells were transferred
to either a 3D RGD hydrogel or 3D omentum hydrogel at a ratio of one
well of a 12-well microwell plate to six 10ll PEG-MAL hydrogels. The
PEG-MAL solution containing MCTS was transferred with cut pipette
tips to minimize shear stress.
Drug screening
Single SKOV-3 cells were seeded in RPMI with 5% FBS and 1%
pen/strep at 6250 cell/cm2 on TCPS 96-well plates. SKOV-3 MCTS
were recovered and encapsulated in 3D hydrogels with the same
medium as TCPS. Samples collected from ascites were seeded in
RPMI with 10% FBS and 1% pen/strep at the same density on TCPS.
Drugs were added after 24 h in the same type of medium that the cells
were seeded in and the cells were incubated with drugs for 48 h.
Carboplatin (Tocris Bioscience, United Kingdom) was added in ten-
fold serial dilutions at concentrations of 2  105 to 2  102 lM.
Paclitaxel (MP Biomedicals, Santa Ana, CA), Mafosfamide (Niomech,
Germany), and Doxorubicin (LC Laboratories, Woburn, MA) were
added in tenfold serial dilutions at concentrations of 1  105 to 1
 102 lM. LY2606368 (AbovChem LLC, San Diego, CA) was added
in tenfold serial dilutions at concentrations of 3 105 to 3 101lM.
Dimethyl sulfoxide (DMSO, Sigma-Aldrich) was used as a vehicle con-
trol for all drugs except Carboplatin was dissolved in water.56 Cell via-
bility was assayed at 24 h postcell seeding in a control plate and after
48 h of drug incubation using the CellTiter-Glo luminescent viability
assay (Promega, Madison, WI). After five (TCPS) or 20 (hydrogels)
min after adding the CellTiter-Glo, luminescence values were mea-
sured using a BioTek Synergy H1 plate reader (BioTek, Winooski,
VT). The drug response metrics were calculated using the online GR
calculator39 found at http://www.grcalculator.org/grcalculator/ for
each cell line and drug combination. For the input file format, we used
the initial cell count calculation method and Case A (multiple cell
counts per row). The variable “replicate” was removed from the
grouping variable list before the data were analyzed. However, the
EC50 values for LY2606368 drug responses of patient 1 and the second
biological replicate of SKOV-3 MCTS in the omentum-inspired
hydrogel were calculated using GraphPad Prism v7.0c (GraphPad
Software, Inc., LaJolla, CA) due to limitations of the GR calculator
with the drug response curves in these cases. Conditions that were
reported as “did not respond in 3D” were determined by meeting one
of or both the following criteria: (1) the output of the GR calculator
defined the relative cell count fit (rather than the GR fit) as “flat”
rather than “sigmoid.” Or (2) all the plotted data points 6 the stan-
dard error of the mean fit within the average drug response 6 the
standard deviation across all concentrations that were tested. The
SKOV-3 data reported are from N  2 independent experiments with
N 2 technical replicates in each experiment.
Immunofluorescence (IF) staining
All antibodies and corresponding dilutions used for IF staining
are listed in Table S1. Single cells seeded on TCPS or MCTS encapsu-
lated in 3D hydrogels for 1 or 3 days were assessed for proliferation via
Ki67 immunofluorescence. For the Ki67 staining, samples were rinsed
with phosphate buffered saline (PBS), fixed with 10% formalin for
15min, permeabilized with tris-buffered saline (TBS) containing 0.5%
Triton X-100 (Promega), and blocked with AbDil [2wt. % bovine
serum albumin (BSA, Thermo) in TBS with 0.1% Triton X-100, TBS-
T] for 20min. Samples were incubated for 1 (TCPS) or 2 (hydrogels)
hours at room temperature with the primary antibody, rinsed three
times with TBS-T, and incubated with a secondary antibody for
1 (TCPS) or 2 (hydrogels) hours. To stain for ECM proteins, the cells
were incubated with the antibodies listed in Table S1 for the incuba-
tion times described above. Cell nuclei were labeled with DAPI
(Thermo) at 1:1000 in phosphate buffered saline (PBS) for five min,
and samples were rinsed three times with PBS. Fluorescence imaging
was performed on a Zeiss Spinning Disc Cell Observer SD (Carl Zeiss
AG, Oberkochen, Germany). The brightness and contrast were
adjusted post-image collection, and SKOV-3 images are representative
from N 2 independent experiments.
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LIVE/DEAD cell viability staining
Cells seeded on TCPS or MCTS encapsulated in 3D hydrogels
for 1 and 3days were assessed for viability with LIVE/DEAD staining
(L3224, Thermo) in accordance with the manufacturer’s instructions.
Imaging was obtained on a Zeiss Spinning Disc Cell Observer SD
(Zeiss). The brightness and contrast were adjusted postimage collec-
tion, and SKOV-3 images are representatives from N 2 independent
experiments.
Statistical analysis
Statistical analysis was performed using GraphPad Prism v7.0c
(GraphPad). Statistical significance was evaluated using a one-way
analysis of variance (ANOVA) followed by a Tukey’s posttest for pair-
wise comparisons. For the analysis, p-values <0.05 are considered sig-
nificant, where p< 0.05 is denoted with , 0.01 with , 0.001 with
, and0.0001 with .
SUPPLEMENTARY MATERIAL
See the supplementary material for antibodies used for immuno-
fluorescence staining, data on hydrogel optimization, and complete
drug response curves.
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